IMP [OUTPERFORM +11.3%] - Strong outlook despite near-term COVID-19 headwinds - Update
  • 2021-08-07T00:00:00
  • Company Research
We reiterate OUTPERFORM as we believe IMP’s leading production technology and ample spare capacity along with a Government policy backdrop that favors high-quality, locally produced drugs in the hospital channel will lead to elevated earnings growth in the next few years